Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 4/20 | 0.37 |
| ▸ | MAOB | P27338 | 4/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 5/20 | 0.36 |
| ▸ | DRD3 | P35462 | 5/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30645785 | 0.85 | DDB1 (0.40) | DRD2ADRA1DSLC6A4ADRA1AADRA1B | |
| SCHEMBL30645741 | 0.80 | MAOB (0.41) | DRD2ADRA1DSLC6A4ADRA1AADRA1B | |
| SCHEMBL4185902 | 0.79 | HRH3 (0.53) | DRD2ADRA1DSLC6A4ADRA1AADRA1B | |
| SCHEMBL30645947 | 0.77 | DRD2 (0.43) | DRD2ADRA1DSLC6A4ADRA1AADRA1B | |
| SCHEMBL30645823 | 0.74 | MAOB (0.41) | DRD2ADRA1DSLC6A4ADRA1AADRA1B | |
| SCHEMBL15545122 | 0.73 | CRBN (0.44) | DDB1CRBNMAOAMAOBHRH3 | |
| SCHEMBL26604815 | 0.72 | MAOB (0.47) | DRD2ADRA1DSLC6A4ADRA1AADRA1B | |
| SCHEMBL30645810 | 0.72 | DRD2 (0.43) | DRD2ADRA1DSLC6A4ADRA1AADRA1B | |
| SCHEMBL3179833 | 0.72 | P2RX3 (0.45) | PTPN1P2RX3NR1H2NR1H3HRH3 | |
| SCHEMBL8338588 | 0.72 | P2RX3 (0.45) | PTPN1P2RX3NR1H2NR1H3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116891-A1 | Oxazepin Derivative | TEIJIN PHARMA LTD (JP) | 2026-04-30 | — | — | US | disclosed |
| EP-4512811-A1 | OXAZEPINE DERIVATIVE | Teijin Pharma Limited (JP) | 2025-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116891-A1 | Oxazepin Derivative | HCRTR2, HCRTR1, OXTR | DRD2 112/4885ADRA1D 53/4885SLC6A4 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.